EFM
PTGX icon

E Fund Management’s Protagonist Therapeutics PTGX Stock Holding History

E Fund Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$477K Sell
3,891
-2,142
-36% -$224K 0.01% 279
2026
Q1 		$636K Buy
+6,033
New +$534K 0.02% 231
2025
Q2 		$497K Buy
8,990
+4,853
+117% +$233K 0.02% 227
2025
Q1 		$200K Sell
4,137
-71,950
-95% -$3.01M 0.01% 362
2024
Q4 		$2.94M Buy
76,087
+4,421
+6% +$193K 0.15% 84
2024
Q3 		$3.22M Buy
+71,666
New +$2.9M 0.17% 65
2024
Q2 		– Sell
-11,304
Closed -$327K – 360
2024
Q1 		$327K Buy
11,304
+2,347
+26% +$63.9K 0.02% 267
2023
Q4 		$205K Sell
8,957
-9,034
-50% -$158K 0.01% 279
2023
Q3 		$300K Buy
17,991
+2,637
+17% +$51.2K 0.02% 210
2023
Q2 		$424K Buy
15,354
+6,641
+76% +$166K 0.03% 153
2023
Q1 		$200K Sell
8,713
-6,769
-44% -$114K 0.01% 302
2022
Q4 		$169K Sell
15,482
-8,366
-35% -$70.6K 0.01% 309
2022
Q3 		$201K Sell
23,848
-12,185
-34% -$115K 0.02% 305
2022
Q2 		$285K Buy
36,033
+25,593
+245% +$309K 0.03% 243
2022
Q1 		$247K Buy
+10,440
New +$294K 0.01% 259

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

E Fund Management's PTGX Position: Q2 2026 in Review

E Fund Management reduced its Protagonist Therapeutics (PTGX) stake by 36% in Q2 2026, selling an estimated $224K and leaving 3,891 shares worth $477K. The position accounts for 0.01% of the portfolio, ranked #279.

E Fund Management first reported a position in PTGX in Q1 2022 and has held it in 15 quarters since. The position peaked at $3.22M in Q3 2024. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • E Fund Management held 3,891 shares of Protagonist Therapeutics worth $477K as of Q2 2026.
  • E Fund Management sold 2,142 Protagonist Therapeutics shares in Q2 2026, an estimated $224K.
  • Protagonist Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #279 holding.
  • E Fund Management first reported a position in Protagonist Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • E Fund Management's Protagonist Therapeutics position peaked at $3.22M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.